DESADENOSINE

Description

Describing and providing medical diagnostic and pharmaceutical preparations with nucleotide sequences that have a low content of, or fully lack, adenosine, for testing, preventing, and therapeutically treating human and non-human animal respiratory ailments that may be associated with hyper-sensitivity or hyper-responsiveness to adenosine, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in many cases are adenosine receptor associated symptoms; pharmaceutical preparations for the treatment of airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating SupraVentricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vascoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g., colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, etc., as well as all other metastatic cancers, e.g., cancers which metastasized to the lung(s), breast, liver and prostate